SDS

Product Name: Smart Spacer, Fiber Spacer Page 7 of 9 Revision date: 10-Jun-2017
999 Production Drive Wakefield MI, 49968
1-906-229-9100
www.extremetool.com
11. TOXICOLOGICAL INFORMATION
Acute Toxicity
LD50/oral/rat:
>5000 mg/kg (estimated)
LD50/dermal/rabbit:
>2000 mg/kg estimated
Inhalation:
Pellet inhalation unlikely due to physical form.
Eye Contact:
Resin particles, like other inert materials, are mechanically irritating to eyes.
Skin Contact:
Not a hazard with pellets during normal industrial use.
Ingestion:
Pellet ingestion unlikely due to physical form.
Chronic Toxicity:
No information available.
Subchronic Toxicity:
No information available
IARC:
Not listed
OSHA:
Not regulated
NTP:
Not tested
Remarks:
The toxicological data has been taken from products of similar composition.
Special Studies: Styrene: A reproduction study in rats exposed to 125 and 250 ppm in drinking water
(approximately 14-21 mg/kg/day) produced no treatment-related effects on reproductive
performance over 3-generations. The only treatment related findings were reduced pup survival
index in the F1 and F2 offspring. There was no evidence of developmental effects and no other
effects were reported. The parental NOEL was 250 ppm and the NOEL for the F1 and F2
offspring was 125 ppm. In developmental toxicity studies in rats, rabbits, and hamsters styrene
was not a selective toxicant to the fetus and was toxic at only those doses that produced
maternal toxicity.
In humans, styrene is associated with central nervous system depression (headache, fatigue,
nausea, and dizziness) at inhalation concentrations greater than 50 ppm. Styrene has also
been reported to reduce sensory nerve conductions in occupation settings after exposure to 100
ppm or more. Styrene has also been reported to produce color vision deficiencies
(dyschromatopsia) at concentrations greater than 8 ppm (averaging 24 ppm). Twelve
epidemiology studies have been reported for styrene and half have supported the hypothesis
that styrene produces lymphatic and hematopoetic cancers (LHC). However, those that show
an increase of LHC has generally been small in size (limited statistical power), have shown no
dose-response relationship, and/or had multiple chemical exposures. Of the six studies that
have not shown an association with styrene and LHC, these studies tended to be larger in size
(higher statistical power), had an older study population, and had good exposure data. Overall,
the weight of evidence suggests that there is not an association of LHC and styrene exposure in
humans.
In a recent inhalation cancer bioassay, Sprague Dawley derived rats (70/sex/group) were
exposed whole body to styrene vapor at 0, 50, 200, 500, or 1000 ppm 6 h/day 5 days/week for
104 weeks. Males exposed to 500 and 1000 ppm and females exposed to 200 ppm and higher
gained significantly less weight than the controls. There were no changes of toxicologic
significance in hematology, clinical chemistry, urinalysis, or organ weights. Styrene-related non-
neoplastic histopathologic changes were confined to the olfactory epithelium of the nasal
mucosa. The incidence and severity were related to dose. There was no evidence that styrene
exposure caused treatment related increases of any tumor type in males or females or in the
number of tumor bearing rats in the exposed groups compared to controls. In 2-year
carcinogenicity bioassays conducted by the National Toxicology Program, rats and mice
(50/sex/group) received 0, 500, 1000, or 2000 mg/kg/day and 0, 150, or 300 mg/kg/day,
respectively, via oral gavage. In male or female rats and female mice there was no significant
difference in tumor incidence when compared to the control groups. In male mice there was a
positive association between styrene dose and the incidence of the combination of adenomas
and carcinomas of the lung. However, due to the high background incidence of this tumor type